Effect of Ursodeoxycholic Acid Use on the Risk of Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ursodeoxycholic acid (UDCA) may modify the risk of inflammatory bowel disease (IBD)-associated colorectal cancer. We performed a systematic review and meta-analysis of studies evaluating the effect of UDCA on the risk of IBD-associated colorectal neoplasia (CRN) (defined as colorectal cancer and/or dysplasia) in patients with primary sclerosing cholangitis with concomitant IBD (PSC-IBD). METHODS: We conducted a systematic search of Medline, Embase, and Web of Science and manually reviewed the literature. Studies were included if they: (1) evaluated exposure to UDCA in patients with PSC-IBD, (2) reported IBD-associated CRN as outcome, and (3) reported relative risks or odds ratios (ORs) or provided data for their calculation. Summary OR estimates with 95% confidence intervals (CIs) were calculated using the random-effects model. RESULTS: Eight studies (5 observational, 3 randomized controlled trials) reporting 177 cases of CRN in 763 patients with PSC-IBD were included in the analysis. Overall, meta-analysis showed no significant protective association between UDCA use and CRN (OR, 0.81; 95% CI, 0.41-1.61). However, there was a significant chemopreventive effect on the risk of advanced CRN (colorectal cancer and/or high-grade dysplasia) (OR, 0.35; 95% CI, 0.17-0.73). In a subgroup analysis, low-dose UDCA use (8-15 mg/kg/d) was associated with significant risk reduction of CRN (OR, 0.19; 95% CI, 0.08-0.49). CONCLUSIONS: UDCA, particularly at low doses, may reduce the risk of advanced CRN in patients with PSC-IBD. However, results should be interpreted with caution, given limited reporting of cancer-related outcomes, primarily from tertiary care centers.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although our data suggest that LCA is a risk factor for liver cancer, UDCA has been previously considered to be protective against colon cancer (39, 40).”
From Bile acid synthesis impedes tumor-specific T cell responses during liver cancer (2025) · cites this paper as [40]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“50% were suggestive of substantial heterogeneity.(28) Because of the small number of published studies, a formal statistical analysis of funnel plot asymmetry for assessment of publication bias was not used.”
BackgroundMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293 · cited 1×
“C olorectal cancer (CRC) is the third most common cancer and the fourth leading cause of cancer-related mortality, worldwide.(1) Patients with inflammatory bowel disease (IBD), particularly those with long-standing extensive ulcerative colitis have a 2- to 5-fold increase in risk of CRC compared with the expected inci…”
BackgroundMeta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“Because of the small number of published studies, a formal statistical analysis of funnel plot asymmetry for assessment of publication bias was not used.(29) All P-values were 2 tailed.”
BackgroundRiddell, R. H., Goldman, H., Ransohoff, D. F., Appelman, H. D., Fenoglio, C. M., Haggitt, R. C., hren, C., Correa, P., Hamilton, S. R., Morson, B. C., et al. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80175-0 · Cited by 1,862
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Cited by
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
“Finally, although mortality in pediatric UC has become rare, a retrospective case collection across Europe over 6 years reported 19 deaths in children with UC mainly due to infections and cancer (1 case of colorectal cancer [CRC]), including 1 with toxic megacolon (10).”
BackgroundInfluentialRole of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
Gordon, H., Burisch, J., Ellul, P., Karmiris, K., Katsanos, K., Allocca, M., Bamias, G., Barreiro-de Acosta, M., Braithwaite, T., Greuter, T., et al. (2024) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjad108 · Cited by 318
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269
Inflammatory bowel disease biomarkers
Liu, D., Saikam, V., Skrada, K. A., Merlin, D., & Iyer, S. S. (2022) · Medicinal Research Reviews · doi:10.1002/med.21893 · Cited by 174
“Manifestations involved in the liver include primary sclerosing cholangitis, which is characterized by inflammation and scarring of bile ducts.(17,18) Manifestations involved in eye include episcleritis, which can cause eye redness, swelling, and inflammation, as well as uveitis.”
BackgroundBile acid synthesis impedes tumor-specific T cell responses during liver cancer
Varanasi, S. K., Chen, D., Liu, Y., Johnson, M. A., Miller, C. M., Ganguly, S., Lande, K., LaPorta, M. A., Hoffmann, F. A., Mann, T. H., et al. (2025) · Science · doi:10.1126/science.adl4100 · Cited by 177
Palmela, C., Peerani, F., Castaneda, D., Torres, J., & Itzkowitz, S. H. (2018) · Gut and Liver · doi:10.5009/gnl16510 · Cited by 177
“49).(124) Therefore, while there might be a protective effect, more studies are needed to draw more definitive conclusions.”
BackgroundDulai, P. S., Sandborn, W. J., & Gupta, S. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0124 · Cited by 172
“(67) However, more recent meta-analyses of population based studies have suggested that a chemoprevention benefit may not exist for all patients, particularly when considering the dose of UCDA used.(68, 69) This lack of benefit with prior chemoprevention studies may be in part due to variability in disease activity, e…”
Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy
Goossens, J., & Bailly, C. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107396 · Cited by 164
Primary sclerosing cholangitis: diagnosis, prognosis, and management
Singh, S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.016 · Cited by 119
Self-citationMolecular cancer prevention: Current status and future directions
Maresso, K. C., Tsai, K. Y., Brown, P. H., Szabo, E. M., Lippman, S. M., & Hawk, E. T. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21287 · Cited by 101
“A few early observational studies and 2 recent meta-analyses have suggested that UDCA may prevent CRC in patients with IBD, particularly in those who also have primary sclerosing choleangitis.(219,223,224) However, some data suggest that high doses of UDCA may actually increase the risk of CRC in patients with primary…”
BackgroundColorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention
Li, W., Zhao, T., Wu, D., Li, J., Wang, M., Sun, Y., & Hou, S. (2022) · Current Oncology · doi:10.3390/curroncol29090479 · Cited by 100
“As mentioned above, high levels of bile acids in colon patients with both IBD and PSC may have carcinogenic effects, ultimately leading to dysplasia or CRC [11,24,172].”
BackgroundKrugliak Cleveland, N., Rubin, D. T., Hart, J., Weber, C. R., Meckel, K., Tran, A. L., Aelvoet, A. S., Pan, I., Gonsalves, A., Gaetano, J. N., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.07.023 · Cited by 85
“Furthermore, a number of metaanalyses also demonstrated a chemoprotective effect for the development of high-grade dysplasia and CRC using low dose UDCA.(30,31) However, these findings have been challenged by additional studies demonstrating no reduction in the incidence of CRC with UDCA(32) and an even higher rate of…”
InfluentialWang, R., & Leong, R. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.8783 · Cited by 81
Kim, Y. S., Hurley, E., Park, Y., & Ko, S. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01042-9 · Cited by 94
From Reflux Esophagitis to Esophageal Adenocarcinoma
Souza, R. F. (2016) · Digestive Diseases · doi:10.1159/000445225 · Cited by 82
Peng, S., Huo, X., Rezaei, D., Zhang, Q., Zhang, X., Yu, C., Asanuma, K., Cheng, E., Pham, T. H., Wang, D. H., et al. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00085.2014 · Cited by 73
Kim, E., Cho, J. H., Kim, E. J., & Kim, Y. J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181183 · Cited by 64
Update on inflammatory bowel disease in patients with primary sclerosing cholangitis
Tsaitas, C. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.178 · Cited by 59
Kim, Y. H., Kim, J. H., Kim, B. G., Lee, K. L., Kim, J. W., & Koh, S. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14526 · Cited by 49
Wijnands, A. M., Mahmoud, R., Lutgens, M. W. M. D., & Oldenburg, B. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.010 · Cited by 48
New Therapeutic Strategies for Primary Sclerosing Cholangitis
Williamson, K., & Chapman, R. (2016) · Seminars in Liver Disease · doi:10.1055/s-0035-1571274 · Cited by 46
Screening for Malignancy in Primary Sclerosing Cholangitis (PSC)
Khaderi, S. A., & Sussman, N. (2015) · Current Gastroenterology Reports · doi:10.1007/s11894-015-0438-0 · Cited by 48
The history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 46
Complications, symptoms, quality of life and pregnancy in cholestatic liver disease
Zakharia, K., Tabibian, A., Lindor, K. D., & Tabibian, J. H. (2018) · Liver International · doi:10.1111/liv.13591 · Cited by 42
“A systematic review involving all these studies showed no significant association between UDCA use and colorectal neoplasia,(39) but there was a 65% reduction of advanced colorectal neoplasia.(39) Until additional studies can confirm the putative chemopreventive properties of UDCA in patients with PSC-IBD, its use for…”
BackgroundBile Acids, Nuclear Receptors and Cytochrome P450
Juřica, J., Dovrtělová, G., Nosková, K., & Zendulka, O. (2016) · Physiological Research · doi:10.33549/physiolres.933512 · Cited by 47
“UDCA in low doses may also prevent from colorectal cancer in patients with concomitant inflammatory bowel disease and PSC (Singh et al. 2013).”
A review of the medical treatment of primary sclerosing cholangitis in the 21st century
Goode, E. C., & Rushbrook, S. M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315605821 · Cited by 41
Inflammatory bowel disease of primary sclerosing cholangitis: A distinct entity?
Nakazawa, T., Naitoh, I., Hayashi, K., Sano, H., Miyabe, K., Shimizu, S., & Joh, T. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3245 · Cited by 46
Malignancies in Primary Sclerosing Cholangitis - A Continuing Threat
Bonato, G., Cristoferi, L., Strazzabosco, M., & Fabris, L. (2015) · Digestive Diseases · doi:10.1159/000440826 · Cited by 39
Gao, R. Y., Shearn, C. T., Orlicky, D. J., Battista, K. D., Alexeev, E. E., Cartwright, I. M., Lanis, J. M., Kostelecky, R. E., Ju, C., Colgan, S. P., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00347-6 · Cited by 37
An Overview on Primary Sclerosing Cholangitis
Vlăduţ, C., Ciocîrlan, M., Bilous, D., Şandru, V., Stan‐Ilie, M., Panić, N., Becheanu, G., Jinga, M., Costache, R. S., Costache, D. O., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030754 · Cited by 40
“UDCA does not have a benefit in preventing colorectal cancer or cholangiocarcinoma, though studies are still underpowered in this field [5,15].”
BackgroundLiver abnormalities in bowel diseases
Kummen, M., Schrumpf, E., & Boberg, K. M. (2013) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.06.013 · Cited by 38
Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence
Bezzio, C., Festa, S., Saibeni, S., & Papi, C. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1292129 · Cited by 36
Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.
Tabibian, J. H., Ali, A. H., & Lindor, K. D. (2018) · Europe PMC (PubMed Central) · Cited by 39
Yang, X., Xu, L., Zhao, H., Xie, T., Wang, J., Wang, L., & Yang, J. (2023) · Nutrition Research · doi:10.1016/j.nutres.2023.02.009 · Cited by 29
Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease
Hsiao, S.-W., Yen, H., & Chen, Y. (2022) · Gut and Liver · doi:10.5009/gnl210479 · Cited by 23
van Heumen, B. W. H., Roelofs, H. M. J., Vink-Börger, M. E., Dekker, E., Mathus-Vliegen, E. M. H., Dees, J., Koornstra, J. J., Langers, A. M. J., Nagtegaal, I. D., Kampman, E., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-118 · Cited by 24
“In contrast, a recent meta-analysis revealed that long-term low dose UDCA treatment (8-15mg/kg daily) reduces the risk of advanced colorectal neoplasms in patients with UC and PSC [43].”
ResultInfluentialFrancini, E., Pazmay, G. V. B., Fumarola, S., Procopio, A. D., Olivieri, F., & Marchegiani, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041759 · Cited by 20
Herfarth, H. H., & Vavricka, S. R. (2021) · Inflammatory Intestinal Diseases · doi:10.1159/000518865 · Cited by 22
Abdel-Latif, M., Inoue, H., & Reynolds, J. V. (2015) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000198 · Cited by 19
Liver involvement in inflammatory bowel disease: What should the clinician know?
Losurdo, G., Brescia, I. V., Lillo, C., Mezzapesa, M., Barone, M., Principi, M., Ierardi, E., Leo, A. D., & Rendina, M. G. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i11.1534 · Cited by 19
Chemoprevention of colorectal cancer in inflammatory bowel disease
Ehrlich, A. C., Patel, S., Meillier, A., Rothstein, R. D., & Friedenberg, F. K. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1283987 · Cited by 18
Current Therapeutics in Primary Sclerosing Cholangitis
Tan, N. P., Lubel, J. S., Kemp, W. W., Roberts, S. K., & Majeed, A. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00068s · Cited by 23
Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations
Jacobs, E. T., Haussler, M. R., Alberts, D. S., Kohler, L. N., Lance, P., Martínez, M. E., Roe, D. J., & Jurutka, P. W. (2016) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0033 · Cited by 16
Rao, B. B., Lashner, B. A., & Kowdley, K. V. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izx056 · Cited by 13
Fousekis, F. S., Mpakogiannis, K. C., Filis, P., Skamnelos, A., Christodoulou, D. K., Mauri, D., & Katsanos, K. H. (2025) · Cancers · doi:10.3390/cancers17020229 · Cited by 13
“Two meta-analyses concluded that only a low dosage of UDCA may benefit patients with IBD and PSC, in terms of CRC development [83,84].”
Recurrent Primary Sclerosing Cholangitis: Current Understanding, Management, and Future Directions
Leung, K. K., Deeb, M., Fischer, S. E., & Gulamhusein, A. F. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730950 · Cited by 12
PSC and colitis: A complex relationship
Horst, L. J., Kempski, J., Walmsley, M., Huber, S., & Schramm, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001236 · Cited by 12
Current Therapies for Cholestatic Diseases
Méndez‐Sánchez, N., Coronel-Castillo, C. E., & Ordóñez-Vázquez, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11061713 · Cited by 12
“One meta-analysis found a protective effect of UDCA for colorectal cancer and/or high-grade dysplasia, which did not hold for early lesions or for overall risk [31].”
BackgroundPreventive effects of 13 different drugs on colorectal cancer: a network meta-analysis
Fu, Q., Liao, H., Li, Z., Chen, X., Zhang, X., & Di, J. (2023) · Archives of Medical Science · doi:10.5114/aoms/167480 · Cited by 11
“Some meta-analyses show that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) [8], aspirin [9], metformin [10], calcium [11], berberine [12], mesalazine [13], statins [14], ursodeoxycholic acid [15], folic acid [16], and other drugs can effectively reduce the incidence of CRC.”
BackgroundSpecific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Fousekis, F. S., Theopistos, V. I., Mitselos, I. V., Skamnelos, A., Kavvadias, A., Katsanos, K. H., & Christodoulou, D. K. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3680 · Cited by 10
An update on treatment options for primary sclerosing cholangitis.
Iravani, S., Moghadam, A. D., Razavi-Khorasani, N., Moazzami, B., Beirami, A. D., Mansour-Ghanaei, A., Majidzadeh‐A, K., Mehrvar, A., Khoshdel, A., Toosi, M. N., et al. (2020) · Gastroenterology and hepatology from bed to bench. · Cited by 13
The role of gut microbiota associated metabolites in digestive disorders
Li, N., Zhao, C., Zhang, P., Wu, S., Dou, X., Xu, S., Zhang, X., Peng, C., Xie, Y., Huang, S., et al. (2024) · Engineered Regeneration · doi:10.1016/j.engreg.2024.04.003 · Cited by 9
Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents
Dyakova, L., Culita, D. C., Marinescu, G., Alexandrov, M., Kalfin, R. E., Patron, L., & Alexandrova, R. (2014) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2014.927973 · Cited by 10
“[16] There are data that UDCA, particularly at low doses, may reduce the risk of advanced colorectal neoplasia (defined as colorectal cancer and/or dysplasia) in patients with primary sclerosing cholangitis with concomitant inflammatory bowel disease.[17] It has been found in our previous investigations that UDCA decr…”
ResultBajer, L., Wohl, P., & Drastich, P. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.090 · Cited by 8
Autorinnen/Autoren, & Collaborators (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2558-5204 · Cited by 10
Interplay of Liver Disease and Gut Microbiota in the Development of Colorectal Neoplasia
Gleeson, M. W. (2019) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-019-00241-6 · Cited by 6
Navigating Neoplasm Risk in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis
Pitoni, D., Buono, A. D., Gabbiadini, R., Ronca, V., Colapietro, F., Pugliese, N., Ribaldone, D. G., Bezzio, C., Lleò, A., & Armuzzi, A. (2025) · Cancers · doi:10.3390/cancers17132165 · Cited by 8
“In contrast, intermediate and high doses (15–30 mg/kg/day) did not change the risk of CRC [103].”
Hu, Y., Lin, C., Zhang, L., Jiang, X., Li, H., & Wu, Y. (2026) · Advanced Science · doi:10.1002/advs.202523582 · Cited by 8
Loosen, S. H., Schmeding, M., Roderburg, C., Binnebösel, M., Temizel, I., Mottaghy, F. M., Tischendorf, J. J. W., Tacke, F., Gaisa, N. T., Hussein, K., et al. (2016) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0042-111048 · Cited by 5
Catalano, M., Mini, E., Nobili, S., Vascotto, I. A., Ravizza, D., Amorosi, A., Tonelli, F., Roviello, F., Roviello, G., & Nesi, G. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i10.108514 · Cited by 5
“Concurrently, incorporating chemopreventive agents[131,132] with established safety and cost-effectiveness profiles, such as 5-ASA, might contribute to modifying disease progression.”
Chen, P.-T., Chien, W.-C., Chung, C., Chen, P., Huang, T., & Chen, H. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.04.007 · Cited by 5
Tenca, A., Jaakkola, T., Färkkilä, M. A., Arola, J. T., & Kolho, K. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1648547 · Cited by 5
Chinese consensus on the prevention of colorectal cancer (2016, S hanghai)
Fang, J., Yong Quan, S. H. I., Chen, Y., Li, J., & Sheng, J. Q. (2017) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12450 · Cited by 5
Primary Sclerosing Cholangitis
Vierling, J. M. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch20 · Cited by 4
Díaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
de Jong, M. J., Zhou, J., Derikx, L. A. A. P., Murad, S. D., van der Meer, A. J., & de Vries, A. C. (2026) · Transplantation · doi:10.1097/tp.0000000000005607 · Cited by 4
Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon
Chapman, R. W. (2014) · Clinical Liver Disease · doi:10.1002/cld.334 · Cited by 3
Trampert, D. C. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.022 · Cited by 2
Chen, Z., Hong, W., Yang, X., Hu, W., & Fang, T. (2025) · Medicine · doi:10.1097/md.0000000000046666 · Cited by 2
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Neoplastic risk for liver and colon in primary sclerosing cholangitis
Båve, A. L., & Bergquist, A. M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.27 · Cited by 3
Epidemiology and Risk Factors for Colorectal Cancer in Inflammatory Bowel Diseases
Murthy, S. K., & Nguyen, G. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-15301-4_1 · Cited by 2
Primary Sclerosing Cholangitis Overlapping with IBD
Sabino, J., tenHove, J., & Torres, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-11446-6_16 · Cited by 1
Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease
Fennimore, B. P., Regner, E. H., & Gerich, M. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_3 · Cited by 1
Huo, X. (2015) · Gastro - Open Journal · doi:10.17140/goj-1-115 · Cited by 1
Singh, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-15301-4_9 · Cited by 1
Self-citationCrohn's Disease: Clinical Manifestations and Management
Melmed, G., & Targan, S. R. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch72 · Cited by 1
Cancer screening and diagnosis in primary sclerosing cholangitis
Skinner, J., Peters, L., Partington, T., & Barnabas, A. (2017) · Gastrointestinal Nursing · doi:10.12968/gasn.2017.15.sup5.s23
Primär sklerosierende Cholangitis
Weismüller, T. J., & Strassburg, C. P. (2018) · Die Gastroenterologie · doi:10.1007/s11377-018-0250-0
“Es gibt außerdemHinweise, dassbei gleichzeitigbestehenderCEDdie Einnahme von UDCA das Risiko fortgeschrittenerkolorektalerNeoplasienreduzieren kann [25].”
Primär sklerosierende Cholangitis
Hoffmann, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-59104-8_33
Complications of Inflammatory Bowel Diseases
Ananthakrishnan, A. N., Xavier, R. J., & Podolsky, D. K. (2017) · Inflammatory Bowel Diseases · doi:10.1002/9781119077633.ch13
Primär sklerosierende Cholangitis
Weismüller, T. J. (2021) · Elsevier eBooks · doi:10.1016/b978-3-437-23847-5.00053-3
Parlak, M. E., Atalay, A., & Yılmaz, A. (2022) · Medical Records · doi:10.37990/medr.1186055
Ogurchyenok, N. E., Khalin, K. D., & Bryukhovetskiy, I. (2024) · Medicine International · doi:10.3892/mi.2024.149
“…produce carcinogenic effects, leading to the proliferation of colonic epithelial cells, ultimately leading to the development of dysplasia or CrC (109,110). researchers have suggested that ursodeoxycholic acid may reduce colonic dysplasia in patients with ulcerative colitis and PSC (110),…”
BackgroundPrimär sklerosierende Cholangitis
Weismüller, T. J. (2024) · Elsevier eBooks · doi:10.1016/b978-3-437-21005-1.00056-1
Zou, M., Yang, Z., Gao, F., & Yang, Z. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.024
Interactions foie-intestin dans la cholangite sclérosante primitive
Kemgang, A. (2019) · theses.fr (ABES) · doi:10.70675/43488c90z3a87z4265z8aeaz1b3e77ed5a3b
Massironi, S., Fanizzi, F., Invernizzi, F., Furfaro, F., Ciocca, L., Arcari, I., Allocca, M., Peyrin‐Biroulet, L., & Danese, S. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2664055
“However, this association remains controversial, as not all studies have confirmed a significant protective effect, and further research is needed to clarify its impact on colorectal carcinogenesis in this high-risk population [43,66].”
Metadata
- Authors
- Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V., & Talwalkar, J. A.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-07
- Volume
- 19
- Issue
- 8
- Pages
- 1631-1638
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2316014275
- Cited by
- 94
- References
- 56
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Inflammatory Bowel Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- ursodeoxycholic acid, primary sclerosing cholangitis
- MeSH terms
- Cholagogues and Choleretics, Humans, Prognosis, Ursodeoxycholic Acid, Colorectal Neoplasms, Meta-Analysis as Topic, Cholangitis, Sclerosing, Inflammatory Bowel Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.